AnaptysBio unveils $100 million stock buyback initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy ANAB?
Stock Repurchase Authorization: AnaptysBio's board has approved an amended stock repurchase plan allowing the company to buy back up to $100 million of its common stock.
Current Repurchase Status: As of November 20, AnaptysBio had $6.4 million remaining under its previous $75 million repurchase plan, having already repurchased 3,443,188 shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANAB
Wall Street analysts forecast ANAB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 52.830
Low
50.00
Averages
74.13
High
140.00
Current: 52.830
Low
50.00
Averages
74.13
High
140.00
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AnaptysBio Q4 Earnings Exceed Expectations
- Earnings Beat: AnaptysBio reported a Q4 GAAP EPS of $1.58, surpassing expectations by $0.71, which reflects a significant improvement in profitability and boosts investor confidence.
- Collaboration Revenue Surge: The company achieved collaboration revenue of $108.25 million, a 151.1% year-over-year increase, exceeding expectations by $21.16 million, indicating strong market competitiveness and successful partnerships.
- Strong Cash Position: As of December 31, 2025, AnaptysBio's cash and investments totaled $311.6 million, ensuring ample funding for future operations and R&D investments.
- Stock Repurchase Program Update: The company has repurchased 3,444,079 shares of common stock, representing 11.2% of outstanding shares, utilizing $68.6 million, demonstrating confidence in its stock value, with the repurchase program set to expire on March 31, 2026.
See More
AnaptysBio Options Trading Analysis
- Options Selling Risks: Selling puts on AnaptysBio does not provide the same upside potential as owning shares, as the put seller only owns shares if the contract is exercised, and if the stock does not fall below $35, the seller only gains a 15.9% annualized return.
- Cost Basis Calculation: If AnaptysBio's stock drops 35.1% and the contract is exercised, the put seller's cost basis would be $32.40 per share after subtracting the $2.60 premium, highlighting the potential risks and rewards of options trading.
- Historical Volatility Analysis: AnaptysBio's historical volatility is calculated at 64%, using the last 251 trading days' closing prices and the current price of $53.97, allowing investors to assess the risk-reward ratio of selling puts at the $35 strike.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, resulting in a put:call ratio of 0.71, indicating a higher demand for puts than the long-term median of 0.65.
See More
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
- FDA Acceptance: Vanda Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target action date set for December 12, 2026, marking a significant milestone in addressing rare diseases.
- Clinical Trial Results: In global clinical studies, a single intravenous dose of imsidolimab resulted in 53% of patients achieving clear or almost clear skin at Week 4, compared to only 13% in the placebo group, demonstrating its potential efficacy in treating GPP.
- Addressing Market Needs: If approved, imsidolimab will be Vanda's third new drug approved in the past 12 months, expected to meet a significant unmet medical need in the rare and life-threatening condition of GPP, enhancing the company's competitive position in the biopharmaceutical market.
- Strategic Investment Outlook: Vanda plans to leverage its commercial infrastructure to promote imsidolimab, with regulatory and patent exclusivity anticipated to extend into the late 2030s, further solidifying its market position in the rare disease sector.
See More
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
- FDA Filing Acceptance: Vanda Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target decision date of December 12, 2026, marking a significant milestone in the company's efforts in rare diseases.
- Clinical Trial Results: In global clinical studies, a single intravenous dose of imsidolimab resulted in 53% of patients achieving clear or almost clear skin at Week 4, compared to 13% in the placebo group, demonstrating its efficacy and potential competitive edge in the market.
- Safety Profile Advantage: Imsidolimab exhibited a favorable safety profile with a low incidence of anti-drug antibodies, providing a significant advantage over existing treatments and addressing the urgent medical needs of GPP patients.
- Market Potential: If approved, imsidolimab will be the third new drug approved for Vanda in the past 12 months, further solidifying its market position in rare disease treatments and driving future growth for the company.
See More
Anaptysbio Biotech Stock Breaks Trendline
- Trendline Break: Anaptysbio's stock cleared a trendline entry near 50 on Monday, indicating strong market momentum that may attract increased investor interest.
- Buy Point Confirmation: The stock is currently in a base with a buy point set at 52.47, and a breakout above this level could trigger a larger buying wave, further driving the stock price upward.
- Positive Market Reaction: Increased investor attention on Anaptysbio may lead to a rise in trading volume in the short term, enhancing liquidity and stabilizing the stock price.
- Technical Analysis: The combination of breaking the trendline and confirming the buy point suggests a bullish sentiment in the market, potentially laying the groundwork for the company's future R&D progress and financial performance.
See More
AnaptysBio Director Sells 3,900 Shares for $193,342.50
- Share Sale: On December 23, AnaptysBio Director J. Anthony Ware sold 3,900 shares at $49.58 each for a total of $193,342.50, reducing his direct holdings by 28.82% from 13,530 to 9,630 shares.
- Ownership Structure: All shares sold were directly held, with no involvement from indirect entities or derivative instruments, indicating Ware's continued economic alignment with the company as he retains 9,630 shares along with options for 126,085 shares and 6,030 restricted stock units.
- Market Performance: Over the past year, AnaptysBio's stock surged more than 260%, significantly outperforming the S&P 500's approximately 17% gain, reflecting strong performance and market confidence in the biotechnology sector.
- Financial Health: As of the end of Q3, AnaptysBio reported $256.7 million in cash and investments, with collaboration revenue rising to $76.3 million from $30 million a year earlier, showcasing the company's innovative capabilities in areas of high unmet medical need.
See More
AnaptysBio Q4 Earnings Exceed Expectations
- Earnings Beat: AnaptysBio reported a Q4 GAAP EPS of $1.58, surpassing expectations by $0.71, which reflects a significant improvement in profitability and boosts investor confidence.
- Collaboration Revenue Surge: The company achieved collaboration revenue of $108.25 million, a 151.1% year-over-year increase, exceeding expectations by $21.16 million, indicating strong market competitiveness and successful partnerships.
- Strong Cash Position: As of December 31, 2025, AnaptysBio's cash and investments totaled $311.6 million, ensuring ample funding for future operations and R&D investments.
- Stock Repurchase Program Update: The company has repurchased 3,444,079 shares of common stock, representing 11.2% of outstanding shares, utilizing $68.6 million, demonstrating confidence in its stock value, with the repurchase program set to expire on March 31, 2026.
See More
AnaptysBio Options Trading Analysis
- Options Selling Risks: Selling puts on AnaptysBio does not provide the same upside potential as owning shares, as the put seller only owns shares if the contract is exercised, and if the stock does not fall below $35, the seller only gains a 15.9% annualized return.
- Cost Basis Calculation: If AnaptysBio's stock drops 35.1% and the contract is exercised, the put seller's cost basis would be $32.40 per share after subtracting the $2.60 premium, highlighting the potential risks and rewards of options trading.
- Historical Volatility Analysis: AnaptysBio's historical volatility is calculated at 64%, using the last 251 trading days' closing prices and the current price of $53.97, allowing investors to assess the risk-reward ratio of selling puts at the $35 strike.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, resulting in a put:call ratio of 0.71, indicating a higher demand for puts than the long-term median of 0.65.
See More
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
- FDA Acceptance: Vanda Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target action date set for December 12, 2026, marking a significant milestone in addressing rare diseases.
- Clinical Trial Results: In global clinical studies, a single intravenous dose of imsidolimab resulted in 53% of patients achieving clear or almost clear skin at Week 4, compared to only 13% in the placebo group, demonstrating its potential efficacy in treating GPP.
- Addressing Market Needs: If approved, imsidolimab will be Vanda's third new drug approved in the past 12 months, expected to meet a significant unmet medical need in the rare and life-threatening condition of GPP, enhancing the company's competitive position in the biopharmaceutical market.
- Strategic Investment Outlook: Vanda plans to leverage its commercial infrastructure to promote imsidolimab, with regulatory and patent exclusivity anticipated to extend into the late 2030s, further solidifying its market position in the rare disease sector.
See More
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
- FDA Filing Acceptance: Vanda Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target decision date of December 12, 2026, marking a significant milestone in the company's efforts in rare diseases.
- Clinical Trial Results: In global clinical studies, a single intravenous dose of imsidolimab resulted in 53% of patients achieving clear or almost clear skin at Week 4, compared to 13% in the placebo group, demonstrating its efficacy and potential competitive edge in the market.
- Safety Profile Advantage: Imsidolimab exhibited a favorable safety profile with a low incidence of anti-drug antibodies, providing a significant advantage over existing treatments and addressing the urgent medical needs of GPP patients.
- Market Potential: If approved, imsidolimab will be the third new drug approved for Vanda in the past 12 months, further solidifying its market position in rare disease treatments and driving future growth for the company.
See More
Anaptysbio Biotech Stock Breaks Trendline
- Trendline Break: Anaptysbio's stock cleared a trendline entry near 50 on Monday, indicating strong market momentum that may attract increased investor interest.
- Buy Point Confirmation: The stock is currently in a base with a buy point set at 52.47, and a breakout above this level could trigger a larger buying wave, further driving the stock price upward.
- Positive Market Reaction: Increased investor attention on Anaptysbio may lead to a rise in trading volume in the short term, enhancing liquidity and stabilizing the stock price.
- Technical Analysis: The combination of breaking the trendline and confirming the buy point suggests a bullish sentiment in the market, potentially laying the groundwork for the company's future R&D progress and financial performance.
See More
AnaptysBio Director Sells 3,900 Shares for $193,342.50
- Share Sale: On December 23, AnaptysBio Director J. Anthony Ware sold 3,900 shares at $49.58 each for a total of $193,342.50, reducing his direct holdings by 28.82% from 13,530 to 9,630 shares.
- Ownership Structure: All shares sold were directly held, with no involvement from indirect entities or derivative instruments, indicating Ware's continued economic alignment with the company as he retains 9,630 shares along with options for 126,085 shares and 6,030 restricted stock units.
- Market Performance: Over the past year, AnaptysBio's stock surged more than 260%, significantly outperforming the S&P 500's approximately 17% gain, reflecting strong performance and market confidence in the biotechnology sector.
- Financial Health: As of the end of Q3, AnaptysBio reported $256.7 million in cash and investments, with collaboration revenue rising to $76.3 million from $30 million a year earlier, showcasing the company's innovative capabilities in areas of high unmet medical need.
See More
